NCT03534323 2026-03-23
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
Clinical Trials
12 trialsNCT02158091 2026-02-13
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT03961672 2026-01-05
Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT05057247 2025-10-31
Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03372057 2025-03-07
PRIMO
SecuraBio
Phase 2 Completed
NCT02204982 2023-09-28
DYNAMO + R
SecuraBio
Phase 3 Terminated
NCT02391545 2023-09-28
A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
SecuraBio
Phase 1/2 Terminated
NCT02004522 2023-09-21
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
SecuraBio
Phase 3 Completed
NCT02049515 2023-09-21
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07
SecuraBio
Phase 3 Completed
NCT04193293 2023-09-21
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
SecuraBio
Phase 1/2 Terminated
NCT02711852 2023-09-11
A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)
SecuraBio
Phase 2 Completed
NCT04209621 2022-03-09
Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated